Ginkgo Bioworks (NYSE: DNA)
Ginkgo Bioworks Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ginkgo Bioworks Company Info
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
News & Analysis
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
They might not be profitable yet, but they're swinging for the fences.
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks.
Is Ginkgo Bioworks Stock a Buy?
There's a lot to like about this business, but it's still a risky bet.
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
It isn't ready for membership today, but it could have a path in the future.
Why Ginkgo Bioworks Stock Is Sinking Today
There wasn't much to like in Ginkgo's Q4 update.
Is Ginkgo Bioworks Stock a Buy Now?
Ginkgo Bioworks says it is experiencing strong growth from its biopharma customers.
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
These two businesses have viable paths to making investors richer -- possibly soon.
Cathie Wood Just Bought These 3 Biotech Stocks. Should You?
They aren't all long shots, but they're all innovative.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.